



Boston Bio Systems Limited

Registered office: A.828, Sun West Bank, Ashram Road, Ahmedabad-380009, Ashram

Road P.O, Ahmedabad, City Taluka, Gujarat, India, 380009

CIN: L31100GJ1995PLC025476; E-mail: bostonsystem@yahoo.com

Website: www.bostonbio.in

Date: 14th August, 2025

To
BSE Limited
Phiroze Jeejeebhoy Towers
Dalal Street
Mumbai, 400001
Maharashtra, India

BSE Symbol: BOSTONBIO

Scrip Code: 531458

Subject: Outcome of the Board Meeting pursuant to Regulation 30 held today i.e. 14th August, 2025 read with Regulation 33 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015

Dear Sir/Madam,

This is to inform you that pursuant to Regulation 30 of the SEBI (Listing Obligations & Disclosure Requirements) Regulations, 2015, the Board of Directors at its meeting held today i.e. **Thursday, 14th August, 2025**, at the Registered Office of the Company inter-alia considered the following business items:

1. Considered and approved the standalone Un-Audited Financial Results of the Company for the Quarter ended on 30th June, 2025. i.e. from 01st April, 2025 to 30th June, 2025.

In compliance with Regulation 33 and other applicable provisions of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 (as amended) the Standalone un-audited Financial Results for the Quarter ended June 30, 2025 of the Company along with Limited Review Report is enclosed.

2. Considered and approved the appointment of Mr. Shashank Kumar, Proprietor of M/s Shashank Kumar & Associates (FRN: S2018UP715500) Practising Company Secretaries as a Secretarial auditor of the company for the Financial Year 2024-25.

The details required under Regulation 30 of the Listing Regulations read with SEBI Circular No. SEBI/HO/CFD/PoD2/CIR/P/0155 dated 11th November 2024 attached below as: Annexure A.



Boston Bio Systems Limited

Registered office: A.828, Sun West Bank, Ashram Road, Ahmedabad-380009, Ashram

Road P.O, Ahmedabad, City Taluka, Gujarat, India, 380009

CIN: L31100GJ1995PLC025476; E-mail: bostonsystem@yahoo.com

Website: www.bostonbio.in

3. Considered and approved the appointment of Mr. Nishant Sharma, Proprietor of M/s Vyom Advisors as the Internal auditor of the company for the Financial Year 2024-25.

The details required under Regulation 30 of the Listing Regulations read with SEBI Circular No. SEBI/HO/CFD/PoD2/CIR/P/0155 dated 11th November 2024 attached below as: Annexure B.

4. Proposed Change in the Name of the Company.

Board of Directors of the Company have duly considered and approved change of the Company's name from "**Boston Bio Systems Limited**" to "**Boston Commerce Limited**", or such other name as approved & subject to approval by the Central Registration Centre (CRC), Ministry of Corporate Affairs and other relevant authority(ies), if any. This change is also subject to the approval of the members in a General Meeting and the subsequent amendment of the Memorandum of Association and Articles of Association of the Company to reflect the name as approved by respective authorities.

The meeting of the Board of Directors commenced at 02:00 p.m. and concluded at 02:45 p.m.

This is for your information and record.

Thanking you.

Yours Faithfully,

**For and on behalf of
Boston Bio Systems Limited**

Ghanshyam Dhananjay Gavali

Managing Director

DIN: 03343352



Boston Bio Systems Limited

Registered office: A.828, Sun West Bank, Ashram Road, Ahmedabad-380009, Ashram

Road P.O, Ahmedabad, City Taluka, Gujarat, India, 380009

CIN: L31100GJ1995PLC025476; E-mail: bostonsystem@yahoo.com

Website: www.bostonbio.in

Annexure-A

Disclosure as per Regulation 30 of the Securities and Exchange Board of India ('SEBI') (Listing Obligations and Disclosure Requirements) Regulations, 2015

1. Appointment of Mr. Shashank Kumar, Proprietor of M/s Shashank Kumar & Associates (Practising Company Secretaries) as Secretarial Auditor of the Company.

S. No.	Particulars	Details
1	Name	Shashank Kumar
2	Designation	Secretarial Auditor
3	Reason for change viz. appointment, resignation, removal, death or otherwise	Appointment as the Secretarial Auditors of the Company for the financial year 2024-2025
4	Date of appointment / cessation (as applicable)	14 th August, 2025
5	Brief Profile	Mr. Shashank Kumar is Member of the Institute of Company Secretaries of India (M. No. 53301) and Proprietor of M/s Shashank Kumar & Associates. He has an experience in the field of Secretarial Compliances. He has handled various compliances related to Corporate Secretarial functions under the Companies Act and the SEBI Regulations.
6	Disclosure of relationship between directors	NA



Boston Bio Systems Limited

Registered office: A.828, Sun West Bank, Ashram Road, Ahmedabad-380009, Ashram

Road P.O, Ahmedabad, City Taluka, Gujarat, India, 380009

CIN: L31100GJ1995PLC025476; E-mail: bostonsystem@yahoo.com

Website: www.bostonbio.in

Annexure-B

Disclosure as per Regulation 30 of the Securities and Exchange Board of India ('SEBI') (Listing Obligations and Disclosure Requirements) Regulations, 2015

2. Appointment of Mr. Nishant Sharma, Proprietor of M/s Vyom Advisors as an Internal Auditor of the Company.

S. No.	Particulars	Details
1	Name	Nishant Sharma
2	Designation	Internal Auditor
3	Reason for change viz. appointment, resignation, removal, death or otherwise	Appointment as the Internal Auditors of the Company for the financial year 2024-2025
4	Date of appointment / cessation (as applicable)	14 th August, 2025
5	Brief Profile	Mr. Nishant Sharma, Proprietor at M/s Vyom advisors is a dedicated professional has an experience in the field of taxation, Auditing etc. He has handled various compliances related to Income Tax, VAT, GST, and such other Acts, Drafting & Finalizing MOUs, Advisory relating to Development and Implementation of Accounting System, Project Finance & Approval
6	Disclosure of relationship between directors	NA



Nahar V. & Company

CHARTERED ACCOUNTANTS

CA Vishal Nahar

B.Com., F.C.A., DISA (I.C.A.I.)

12, Bajaj Khana, JAORA ; Dist. Rattlam
☎ : 07414-221253, 222652
Mob. 98272 73710, Fax : 0731-2577943
E-mail : vnaharin@yahoo.com

Ref.

Date :

Independent Auditor's Review Report on Standalone Unaudited Quarterly Financial Results to Standalone Unaudited Year to Date Results of the Company Pursuant to the Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended

Review Report to
The Board of Directors
Boston Bio Systems Limited

1. We have reviewed the accompanying Statement of Standalone Unaudited Financial Results ("Statement") of **Boston Bio Systems Limited** ("the Company") for the quarter ended 30 June 2025 ("the Statement") attached herewith, being submitted by the Company pursuant to the requirements of Regulation 33 of the SEBI ((Listing Obligations and Disclosure Requirements) Regulation, 2015 (the "Regulation") as amended, including relevant circulars issued by the SEBI from time to time.
2. This statement, which is the responsibility of the Company's Management and approved by the Board of Directors, has been compiled from the related audited interim standalone financial information which has been prepared in accordance with the recognition and measurement principles laid down in the Indian Accounting Standard 34 "Interim Financial Reporting" (Ind AS 34), prescribed under Section 133 of the Companies Act, 2013 read with relevant rules issued thereunder and other accounting principles generally accepted in India. Our responsibility is to express an opinion on the Statement based on our review.
3. We conducted our review of the Statement in accordance with the Standard on Review Engagement (SRE) 2410, "Review of Interim Financial Information Performed by the Independent Auditor of the Entity" issued by the Institute of Chartered Accountants of India. This standard requires that we plan and perform the review to obtain moderate assurance as to whether the statements are free of material misstatements. A review of interim financial information consists of making inquiries, primarily of persons responsible for financial and accounting matters, and applying analytical and other review procedures. A review is substantially less in scope than an audit conducted in accordance with the Standards on Auditing specified under section 143(10) of the Act, and consequently, does not enable us to obtain assurance that we would become aware of all significant matters that might be identified in an audit. Accordingly, we do not express an audit opinion.



4. Based on our review conducted as stated above, nothing has come to our attention that causes us to believe that the accompanying statement, prepared in accordance with the recognition and measurement principles laid down in the Indian Accounting Standards 34 (Ind AS-34) specified under section 133 of the Companies Act, 2013 as amended, read with relevant rules issued thereunder and other recognized accounting practices and policies has not disclosed the information required to be disclosed in terms of the Regulation, read with circular, including the manner in which it is to be disclosed, or that it contains any material misstatement

For
Chartered Accountants
Firm Registration No. 010443C



CA VISHAL NAHAR
Proprietor
M. No.: 400217
UDIN: 25400217BMLCUV1591



Place: INDORE
Date: 14.08.2025

BOSTON BIO SYSTEMS LIMITED

CIN: L31100GJ1995PLC025476

Registered Office: A.828, Sun West Bank, Ashram Road, Ashram Road P.O,
Ahmedabad, City Taluka, Gujarat-380009, India

STATEMENT OF UNAUDITED FINANCIAL RESULTS FOR THE QUARTER ENDED JUNE 30, 2025

Sl. No.	Particulars	(Rs. in lakhs)			
		Quarter ended		Year ended	
		30-Jun-25	31-Mar-25	30-Jun-24	31-Mar-25
		Unaudited	Audited	Unaudited	Audited
1	Income				
	a) Revenue from operations				
	b) Other income	18.05	19.25	-	19.25
	Total income	-	-	-	-
		18.05	19.25	-	19.25
2	Expenses				
	a) Purchase of stock in trade	-	-	-	-
	b) Changes in inventories of stock in trade	-	-	-	-
	c) Employee benefits expense	-	-	-	-
	d) Finance costs	3.36	-	-	-
	e) Depreciation and amortisation expense	-	-	-	-
	f) Other expenses	-	-	-	-
	Total expenses	9.33	68.30	-	73.98
		12.69	68.30	-	73.98
3	Profit / (Loss) before exceptional items and tax (1-2)				
		5.36	(49.05)	-	(54.73)
4	Exceptional items	-	-	-	-
5	Profit / (Loss) before tax (3-4)				
		5.36	(49.05)	-	(54.73)
6	Tax expense				
	a) Current tax	1.35	-	-	-
	b) Deferred tax	-	-	-	-
7	Profit / (Loss) after Tax (5-6)				
		4.01	(49.05)	-	(54.73)
8	Other comprehensive income				
	a) Items that will not be reclassified to profit and loss				
	Re-measurement gains (losses) on defined benefit plans	-	-	-	-
	Income tax effect	-	-	-	-
	b) Income tax relating to items that will not be reclassified to profit and loss	-	-	-	-
	Net other comprehensive income to be reclassified to profit or loss in subsequent periods	-	-	-	-
	Income tax effect	-	-	-	-
	Total other comprehensive income / (loss) for the year	-	-	-	-
9	Total comprehensive income / (loss) for the period/year (7+8)				
		4.01	(49.05)	-	(54.73)
10	Paid up equity share capital (face value of Rs. 10 per share)	700.22	700.22	700.22	700.22
11	Other equity	-	-	-	(109.77)
12	Earnings per equity share (face value of Rs. 10 per share)				
	Basic (Rs.)	0.06	(0.70)	-	(0.78)
	Diluted (Rs.)	0.06	(0.70)	-	(0.78)

Note:

- The unaudited standalone financial results have been reviewed and approved by the board of directors at their meeting held on 14th August, 2025. In compliance with the securities and exchange board of India (Listing Obligations and Disclosure Requirements) Regulations as amended, 2015 ("SEBI Listing Regulations"), a A115 limited review of the above results has been carried out by the statutory auditors of the company.
- The above results for the quarter ended on 30 June 2025 have been prepared in accordance with the recognition and measurement principles laid down in the Indian Accounting Standard 34 "Interim Financial Reporting" (Ind AS 34), prescribed under Section 133 of the Companies Act, 2013 read with relevant rules issued thereunder and other accounting principles generally accepted in India.
- The company has a single reportable segment for the purpose of Ind AS-108.
- The figures for the previous period have been regrouped / rearranged / reclassified wherever necessary.

For and on behalf of the Board of Directors
For BOSTON BIO SYSTEMS LIMITED

Ashishyam Dhananjay Gavali
Managing Director
DIN: 03343352



Place: Gujarat
Date: 14-08-2025